IMPAACT at CROI 2022
The IMPAACT Network presented 17 abstracts from 12 studies (3 oral presentations, 14 poster presentations) at the Conference on Retroviruses and Opportunistic Infections (CROI) 2022. The conference took place virtually from February 12-16.
See below for full abstract listing. Presentations will be added as they become available.
View the recordings of presentations given to the ICAB in English, Spanish, Portuguese, and Thai here.
MONDAY, 14 FEBRUARY
|
Protocol |
Title |
Authors |
Presentation Type & Time |
|
Growth Of Infants with Perinatal Exposure to Maternal DTG vs EFV and TDF vs TAF |
Stranix-Chibanda L, Ziemba L, Brummel S, Johnston B, Mbengeranwa T, Cassim H, Theron G, Ngqawana Z, Wabwire D, McCarthy K, Chakhtoura N, Jean-Philippe P, Chinula L, Lockman S, for the IMPAACT 2010/VESTED study team and investigators |
Oral Presentation Maternal and Child Health: New Insights into Hepatitis, SARS- CoV-2 and HIV Session 9:45 AM – 11:45 AM MT |
|
|
Two Year Virologic Outcomes of Very Early ART for Infants in the IMPAACT P1115 Study |
Persaud D, Chadwick EG, Nelson BS, Tierney C, Cotton MF, Coletti A, Costello D, Nicodimus N, Stranix-Chibanda L, Kekitiinwa AR, Reding C, Majji S, Jean-Philippe P, Bryson Y, for the IMPAACT P1115 Team |
Oral Presentation Maternal and Child Health: New Insights into Hepatitis, SARS- CoV-2 and HIV Session 9:45 AM – 11:45 AM MT |
|
|
Pregnancy Hemoglobin A1c and glucose with DTG vs EFV, TDF vs TAF: IMPAACT 2010 |
Chinula L, Goldberg E, Ziemba L, McCarthy K, Krotje C, Knowles K, Mathad J, Santos Cruz ML, Hoffman R, Jean-Philippe P, Chipato T, Wabwire D, Currier J, Lockman S, Chakhtoura N |
Poster Presentation Evolving Insights: MTCT Risk to Maternal Health Session 2:00 PM – 3:30 PM MT |
|
| NICHD P1081 | Weight Gain with Raltegravir vs. Efavirenz During Pregnancy | Coutinho CM, Warshaw M, Duarte G, Stek A, Violari A, Hofer CB, Deville J, Ngocho JS, Pilotto J, Correa Jr MD, Fuller T, Chakhtoura N, Mirochnick M, João E |
Poster Presentation Evolving Insights: MTCT Risk to Maternal Health Session 2:00 PM – 3:30 PM MT |
|
Association of Maternal TDF-containing ART with Bone Mineral Content in Breastfed Infants |
Vhembo T, Baltrusaitis K, Tierney C, Owor M, Dadabhai S, Violari A, Theron G, Moodley D, Kahari-Mukwasi C, George K, Shepherd J, Siberry G, Fowler MG, and Stranix-Chibanda L, for the IMPAACT P1084s Study Team |
Poster Presentation New Perspectives on the Health of Children Exposed to HIV In Utero Session 2:00 PM – 3:30 PM MT |
|
| IMPAACT P1078 | Maternal IPT In Pregnancy and Growth Faltering Among HIV-Exposed Uninfected Infants | Cherkos AS, LaCourse S, Enquobahrie DA, Montepiedra G, Onyanog C, Mmbaga BT, Vhembo T, Masheto G, Theron G, Weinberg A, Gupta A, John-Stewart G |
Poster Presentation New Perspectives on the Health of Children Exposed to HIV In Utero Session 2:00 PM – 3:30 PM MT |
|
HIV Drug Resistance in Women Randomized to DTG vs EFV or TDF vs TAF in Pregnancy |
Boyce C, Ziemba L, Brummel S, McCarthy K, Knowles K, Styrchak S,Browning R, Chakhtoura N, Moyo S, Vhembo T, Korutaro V, Pilotto JH, Chinula L, Lockman S, Frenkel LM |
Poster Presentation Impact of HIV Mutations on Fitness, Drug Resistance, and Treatment Response Session 2:00 PM – 3:30 PM MT |
Tuesday, 15 February
|
Protocol |
Title |
Authors |
Presentation Type & Time |
|
HIV-1 Remission with CCR5Δ32Δ32 Haplo-Cord Transplant in a US Woman: IMPAACT P1107 |
Hsu J, Van Besien K, Glesby M, Coletti A, Pahwa S, Warshaw M, Golner A, Bone F, Tobin N, Riches M, Mellors J, Browning R, Persaud D, Bryson Y, and the IMPAACT P1107 Team |
Oral Presentation HIV Reservoirs and Cure Strategies Session 9:45 AM – 11:45 AM MT |
|
| IMPAACT 2010 | Risk-benefit Trade-off for Pregnancy and Infant Outcomes: DTG, EFV, TAF, and TDF | Brummel S, Ziemba L, Coletti A, Chinula L, Krotje C, Browning R, Chakhtoura N, João E, Raesi M, Ngocho J, Aurpibul L, Stranix-Chibanda L, Shapiro R, Stringer J, Lockman S |
Poster Presentation HIV, ART, and Pregnancy Outcomes: Epidemiology and Mechanisms Session 2:00 PM – 3:30 PM MT |
|
Adverse Outcomes in Subsequent Pregnancies in the IMPAACT 2010 Trial |
Fairlie L, Brummel S, Ziemba L, Coletti A, Chinula L, Shapiro R, Stringer J, Browning R, Chakhtoura N, Mmbaga BT, Mhembere T, Masheto G, Nagaddya B, Naidoo M, Lockman S |
Poster Presentation HIV, ART, and Pregnancy Outcomes: Epidemiology and Mechanisms 2:00 PM – 3:30 PM MT |
|
|
Matovu FK, Tierney C, Chang A, Moodley D, Govender V, Vhembo T, Mohtashemi N, Ship H, Musoke P, Dula D, George K, Chakhtoura N, Peters MG, Fowler MG, Currier JS, Bhattacharya D |
Poster Presentation HIV, ART, and Pregnancy Outcomes: Epidemiology and Mechanisms 2:00 PM – 3:30 PM MT |
||
|
Is Routine PCP Prophylaxis Needed in Very Early-treated Infants with HIV? |
Nelson BS, Tierney C, Persaud D, Jao J, Cotton MF, Bryson Y, Bacon K, Costello D, Perlowski C, Santos Cruz ML, Kosgei J, Majji S, Yin D, Chadwick EG, for the IMPAACT P1115 Team |
Poster Presentation Early Treatment and HIV Reservoirs in Children Session 2:00 PM – 3:30 PM MT |
|
|
IMPAACT 2032: Remdesivir PK & Safety in Pregnant and Non-pregnant Women with COVID-19 |
Brooks KM, Baltrusaitis K, Momper J, Greene E, Bone F, Bacon K, Humeniuk R, Yin DE, Chakhtoura N, Stek AM, Capparelli E, Mirochnick M, Clarke DF, Best B, on behalf of the IMPAACT 2032 Study Team |
Poster Presentation COVID-19 in Mothers and Their Children Session 2:00 PM – 3:30 PM MT |
Wednesday, 16 February
|
Protocol |
Title |
Authors |
Presentation Type & Time |
|
Extended Safety and PK and Anti-HIV Monoclonal AB VRC07-523LS in HIV-exposed Infants |
Cunningham CK, Capparelli EV, McFarland EJ, Muresan P, Perlowski C, Yin D, Moye J, Majji S, Purdue L, Harding PA, McDermott A, Mascola JR, Graham BS, for the IMPAACT P1112 team |
Poster Presentation PK, Safety, and Acceptability of New Agents for Children and Youth Session 2:00 PM – 3:30 PM MT |
|
| IMPAACT 2019 | IMPAACT 2019: PK & Safety of Dispersible ABC/DTG/3TC in Children with HIV 6 to <14 kg | Brooks KM, Kiser JJ, Rani Y, Masheto GR, Patel F, Mustich I, Heckman B, Lojacono M, Yin DE, Majji S, Chandasana H, Rabie H, Flynn P, on behalf of the IMPAACT 2019 Team |
Poster Presentation PK, Safety, and Acceptability of New Agents for Children and Youth Session 2:00 PM – 3:30 PM MT |
| IMPAACT 2017 | Safety and PK of Long-acting Cabotegravir and Rilpivirine in Adolescents | Bolton Moore C, Capparelli E, Calabrese K, Best B, Ward S, McCoig C, Crauwel H, Agwu A, Samson P, Heckman B, Ford S, Adeyeye A, Moye J, Camacho-Gonzalez A, Gaur AH |
Poster Presentation PK, Safety, and Acceptability of New Agents for Children and Youth Session 2:00 PM – 3:30 PM MT |
|
Adolescent and Parent Experiences with Long- acting Injectables in the MOCHA Study |
Lowenthal, E.D., Chapman J, Calabrese K, Milligan R, Agwu A, Camacho-Gonzalez A, Smith-Anderson C, Kneebone J, McCoig C, Harrington C.M., Van Solingen-Ristea R, Adeyeye A, Moye J, Bolton Moore C, Gaur A.H. |
Poster Presentation PK, Safety, and Acceptability of New Agents for Children and Youth Session 2:00 PM – 3:30 PM MT |